Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Lisa Gill | JPMorgan | 8 questions · 0% challenging |
| Daniel Grosslight | Citigroup | 7 questions · 0% challenging |
| Elizabeth Anderson | Evercore ISI | 7 questions · 0% challenging |
| Allen Lutz | Bank of America | 7 questions · 0% challenging |
| Brian Tanquilut | Jefferies | 7 questions · 0% challenging |
| Eric Percher | Nephron Research | 7 questions · 0% challenging |
| Erin Wright | Morgan Stanley | 7 questions · 0% challenging |
| Kevin Caliendo | UBS | 6 questions · 33% challenging |
| Steve Baxter | Wells Fargo | 6 questions · 0% challenging |
| George Hill | Deutsche Bank | 6 questions · 0% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| JPMorgan | 1 analyst | 8 questions · 0% challenging |
| Citigroup | 1 analyst | 7 questions · 0% challenging |
| Bank of America | 1 analyst | 7 questions · 0% challenging |
| Evercore ISI | 1 analyst | 7 questions · 0% challenging |
| Jefferies | 1 analyst | 7 questions · 0% challenging |
| Leerink Partners | 2 analysts | 7 questions · 0% challenging |
| Morgan Stanley | 1 analyst | 7 questions · 0% challenging |
| Nephron Research | 1 analyst | 7 questions · 0% challenging |
No 8-K events recorded for this window.
Calendar quarter Q1 2026Earnings call May 7, 2026
FY2026 Q4 in brief
Consolidated revenue grew 6% to $96.3 billion with adjusted EPS of $11.69, up 16%, capping a full year of 18% adjusted EPS growth.
Newest quarter FY2027 Q1 is part of Pro · see what Pro adds →
Sources. Tellvest earnings-call sentiment score for McKesson Corporation (MCK), FY2026 Q4: 8/10. Scores: McKesson Corporation’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: MCK daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
Consolidated revenue grew 6% to $96.3 billion with adjusted EPS of $11.69, up 16%, capping a full year of 18% adjusted EPS growth. The Medical-Surgical separation with Apollo investment was announced while 570+ oncology providers were added and the biopharma services division delivered a record verification season. Management introduced FY2027 EPS guidance of $43.80-$44.60 with operating cash flow of $6.2 billion exceeding plans.
GAAP revenue YoY +6.02% → base 6. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
Competitive Dynamics | Demand | Guidance Reliability | Margin | Revenue Growth | M&A | Innovation & R&D | Regulation Policy | |
|---|---|---|---|---|---|---|---|---|
| 2025Q2 | 2 | 4 | 4 | 5 | 2 | 1 | 2 | |
| 2025Q3 | 4 | 3 | 2 | 2 | 1 | 3 | 1 | |
| 2025Q4 | 3 | 1 | 2 | 1 | 2 | 1 | 1 | 2 |
| 2026Q1 | 3 | 4 | 2 | 1 | 3 | 1 | 2 | 3 |
| 2026Q2 | 5 | 3 | 5 | 3 | 1 | 3 | 2 | 2 |
| 2026Q3 | 3 | 2 | 3 | 3 | 4 | 2 | 4 | 1 |
| 2026Q4 | 3 | 3 | 1 | 1 | 2 | 2 | 1 | 2 |
| '25Q2 | '25Q3 | '25Q4 | '26Q1 | '26Q2 | '26Q3 | '26Q4 | |
|---|---|---|---|---|---|---|---|
| Competitive Dynamics | 2 | 4 | 3 | 3 | 5 | 3 | 3 |
| Demand | 4 | 3 | 1 | 4 | 3 | 2 | 3 |
| Guidance Reliability | 4 | 2 | 2 | 2 | 5 | 3 | 1 |
| Margin | 5 | 2 | 1 | 1 | 3 | 3 | 1 |
| Revenue Growth | 2 | 1 | 2 | 3 | 1 | 4 | 2 |
| M&A | 1 | 3 | 1 | 1 | 3 | 2 | 2 |
| Innovation & R&D | 2 | 1 | 1 | 2 | 2 | 4 | 1 |
| Regulation Policy | 2 | 3 | 2 | 1 | 2 |
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2025 Q2 | $93.65B | +21.3% | $1.87 | -62.0% | 3.5% | 0.6% | 0.3% | $1.96B |
| FY2025 Q3 | $95.29B | +17.8% | $6.95 | +57.2% | 3.4% | 1.3% | 0.9% | $-2.51B |
| FY2025 Q4 | $90.82B | +18.9% | $10.01 | +66.3% | 4.0% | 1.8% | 1.4% | $7.58B |
| FY2026 Q1 | $97.83B | +23.4% | $6.25 | -10.7% | 3.4% | 1.1% | 0.8% | $-1.03B |
| FY2026 Q2 | $103.15B | +10.1% | $8.92 | +377.0% | 3.4% | 1.4% | 1.1% | $2.31B |
| FY2026 Q3 | $106.16B | +11.4% | $9.59 | +38.0% | 3.5% | 1.5% | 1.1% | $1.12B |
| FY2026 Q4Selected | $96.30B | +6.0% | $13.71 | +37.0% | 4.2% | 2.2% | 1.7% | $3.31B |
| FY2027 Q1 | $105.38B | +7.7% | $5.15 | -17.6% | 3.5% | 1.3% | 0.6% | $-332M |
| Year | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin |
|---|
What MCK said about other companies on its FY2026 Q4 call, and what other companies said about MCK on their calls covering the same calendar quarter (Q1 2026). Each company's own fiscal quarter is shown next to its name. Extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“this outcome was achieved through direct negotiations with Baylor and McKesson, leveraging decades-long relationships and in-house operating platform”
Healthpeak negotiated the Baylor cancer-center lease renewals directly with Baylor and McKesson, indicating McKesson's involvement (US Oncology) as a party in the outpatient oncology real estate.
“Ontada, our data and insights business, for example, is now incorporating in-office dispensing data from Florida Cancer Specialists and Research Institute.”
| Net margin |
|---|
| FCF |
|---|
| FY2023 | $276.71B | +4.8% | $25.05 | +247.4% | 4.5% | 1.6% | 1.3% | $4.77B |
| FY2024 | $308.95B | +11.7% | $22.38 | -10.7% | 4.2% | 1.3% | 1.0% | $3.88B |
| FY2025 | $359.05B | +16.2% | $25.83 | +15.4% | 3.7% | 1.2% | 0.9% | $5.55B |
| FY2026Selected | $403.43B | +12.4% | $38.47 | +48.9% | 3.6% | 1.5% | 1.2% | $5.72B |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
McKesson's Ontada data business is now incorporating in-office dispensing data from Florida Cancer Specialists and Research Institute to expand its biopharma insights.
“We also had 3 quarters of revenue related to Rite Aid.”
McKesson is lapping three quarters of distribution revenue tied to Rite Aid, a revenue (though minimal income) headwind in fiscal 2027.
“We also announced a definitive agreement with Apollo Funds for a $1.25 billion strategic minority investment in Medical-Surgical Solutions, representing approximately 13% minority interest and valuing NewCo at approximately $13 billion of total enterprise value.”
Apollo is making a $1.25 billion strategic minority investment (~13%) in McKesson's Medical-Surgical Solutions carve-out, valuing NewCo at ~$13 billion.
| Company | Score | Trend | Rev YoY | Headline |
|---|---|---|---|---|
| MCKMcKesson Corporation | 8 | +6.0% | Consolidated revenue grew 6% to $96.3 billion with adjusted EPS of $11.69, up 16%, capping a full year of 18% adjusted EPS growth | |
| CAHCardinal Health | 9 | +11.1% | Pharmaceutical distribution demand strong with 11% revenue growth | |
| CORCencora | 8 | +3.9% | Revenue Growth Slowing on Multiple Fronts | |
| HSICHenry Schein | 6 | +6.3% | Henry Schein's first quarter under new CEO Fred Lowery delivered 6.3% revenue growth to $3.4 billion with non-GAAP operating margin expanding 28 basis points to 7.53%, as US dental merchandise accelerated to 5.6% growth with market share gains and corporate brand momentum |
Consolidated revenue grew 6% to $96.3 billion with adjusted EPS of $11.69, up 16%, capping a full year of 18% adjusted EPS growth
Pharmaceutical distribution demand strong with 11% revenue growth
Henry Schein's first quarter under new CEO Fred Lowery delivered 6.3% revenue growth to $3.4 billion with non-GAAP operating margin expanding 28 basis points to 7.53%, as US dental merchandise accelerated to 5.6% growth with market share gains and corporate brand momentum
| Company | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|---|
| MCK | 9 | 9 | 9 | 9 | 8 | 8 |
| CAH | 6 | 7 | 6 | 10 | 10 | 9 |
| COR | 7 | 9 | 9 | 8 | 8 | 8 |
| HSIC | 8 | 5 | 6 | 7 | 6 | 6 |